Evaluating the Effects of GLP-1 Receptor Agonists on Hepatic Function in Patients with Type 1 Diabetes (ELEGANT-T1D)
The goal of this study is to learn how certain medicines, like Ozempic and Mounjaro, affect the liver in people with type 1 diabetes. We are especially looking at a liver disease called MASLD (MASLD (metabolic dysfunction-associated steatotic liver disease), which happens when the liver builds up too much fat.
Why this Research Matters
You will complete questionnaires about your health and lifestyle, have blood drawn, and complete a liver ultrasound. You will participate in either a 1-time visit or be followed for up to 1 year (if intending to start a GLP-1 medication, like Ozempic or Mounjaro). Please reach out to Scott Maclean at scott.2.maclean@cuanschutz.edu or 303-724-8348 or complete the following survey: https://redcap.link/elegant_t1d_prescreen.
Who can Participate
You may be able to join the study if you are between 18 and 80 years old. You must either not have diabetes or have had T1D for at least 15 years. If you have T1D, you must have never taken a GLP-1 RA medicine like Ozempic or Mounjaro, or have been taking one for at least 1 year. You cannot join the study if you have had weight-loss surgery or if you are pregnant.
Study ID
Protocol Number: 25-2469
Meet the Team
Scott Maclean
Principal Investigator